News
OHE responds to the 2025 UK Budget
26 November 2025
Commenting on the newly announced 2025 UK Budget, Professor Graham Cookson, Chief Executive of the Office of Health Economics, said: “The NHS’ long-term sustainability will only come…
New research reveals, in carers’ own words, the multidimensional burden of caring for leukemia patients
20 November 2025
Today, the Acute Leukemia Advocates Network (ALAN) and the Office of Health Economics (OHE published a first-of-its-kind qualitative study of informal carers across 6 countries.
New evaluation model finds widespread adoption of cell and gene therapies may unlock billions for the UK economy
20 October 2025
A new report published today by the Cell and Gene Therapy Catapult (CGT Catapult) and the Office of Health Economics (OHE) presents a new method of quantifying the economic impact of healthcare innovations, such as cell and gene therapies.
New OHE model estimates COVID-19 could be associated with costs of £7 billion a year in the UK, without annual autumn vaccinations
13 October 2025
A newly released report commissioned by Moderna modelled a one-year scenario without annual COVID-19 autumn vaccinations.
OHE responds to the NHS Ten Year Plan
3 July 2025
Professor Graham Cookson responds to the Ten Year Health Plan for England.
OHE statement on 2025 Spending Review
11 June 2025
Professor Graham Cookson responds to Chancellor’s Spending Review announcement boosting NHS spend by 3%.
OHE responds to the Trump administration’s Executive Order on Drug Prices
14 May 2025
Professor Graham Cookson responds to President Donald Trump’s Executive Order on drug prices published earlier this week.
OHE to host the Health Economists’ Study Group Summer 2025
6 March 2025
The Health Economists’ Study Group Summer Meeting will run from 30th June – 2nd July 2025.
OHE’s submission to Belgium’s Committee on Health and Equal Opportunities argues value-based pricing delivers a ‘triple-win’
18 December 2024
Professor Cookson argues that value-based pricing would benefit patients and health systems while ensuring ongoing investment in pharmaceutical innovation is incentivised.